UB Paderborn / Katalog / Suche / in CDI

Effect of Human Renal Cationic Transporter Inhibition on the Pharmacokinetics of Varenicline, a New Therapy for Smoking Cessation: An In Vitro–In Vivo Study

Clinical pharmacology and therapeutics, 2008-04, Vol.83 (4), p.567-576

2008

Link zum Volltext

Verfügbarkeit prüfen

2502 TAK-385, an oral GnRH antagonist: efficacy and safety results from a randomized phase 2 trial in prostate cancer patients (pts)

European journal of cancer (1990), 2015-09, Vol.51, p.S474-S474

2015

Link zum Volltext

Verfügbarkeit prüfen

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes

Blood cancer journal (New York), 2017-02, Vol.7 (2), p.e520-e520

2017

Link zum Volltext

Verfügbarkeit prüfen

Quantitative Assessment of Exposure-Response Relationships for the Efficacy and Tolerability of Varenicline for Smoking Cessation

Clinical pharmacology and therapeutics, 2010-03, Vol.87 (3), p.336-344

2010

Link zum Volltext

Verfügbarkeit prüfen

Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers

European journal of clinical pharmacology, 2008-11, Vol.64 (11), p.1101-1109

2008

Link zum Volltext

Verfügbarkeit prüfen

The safety, tolerability, pharmacodynamics, and pharmacokinetics of oral TAK-994 in sleep deprived healthy male subjects

Sleep medicine, 2024-02, Vol.115, p.227-228

2024

Link zum Volltext

Verfügbarkeit prüfen

Plasma level-dependent effects of methylphenidate on task-related functional magnetic resonance imaging signal changes

Psychopharmacology, 2005-08, Vol.180 (4), p.624-633

2005

Link zum Volltext

Verfügbarkeit prüfen

Results of a phase 1, 4-period crossover, placebo-controlled, randomized, single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-925, a novel orexin 2 receptor agonist, in sleep-deprived healthy adults, utilizing modafinil as an active comparator

Sleep medicine, 2019-12, Vol.64, p.S106-S106

2019

Link zum Volltext

Verfügbarkeit prüfen

Ranitidine, 75 mg, over‐the‐counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro‐oesophageal reflux

Alimentary pharmacology & therapeutics, 2002-05, Vol.16 (5), p.899-907

2002

Link zum Volltext

Verfügbarkeit prüfen

The Search for Cytotoxic Synergy Between Anticancer Agents: a Case of Dorothy and the Ruby Slippers?

JNCI : Journal of the National Cancer Institute, 1996-06, Vol.88 (11), p.699-700

1996

Link zum Volltext

Verfügbarkeit prüfen

A Phase 1 single ascending dose study of a novel orexin 2 receptor agonist, TAK-925, in healthy volunteers (HV) and subjects with narcolepsy type 1 (NT1) to assess safety, tolerability, pharmacokinetics, and pharmacodynamic outcomes

Sleep medicine, 2019-12, Vol.64, p.S105-S106

2019

Link zum Volltext

Verfügbarkeit prüfen

Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: The critical role of polyglutamylation

Cancer research (Chicago, Ill.), 1998-07, Vol.58 (14), p.3036-3050

1998

Link zum Volltext

Verfügbarkeit prüfen

Neo/adjuvant ADT to EBRT: Randomized phase 2 trial of the oral GnRH antagonist, TAK-385 (relugolix, RGX) and degarelix (DGX) in patients (pts) with prostate cancer (PC)

Annals of oncology, 2016-10, Vol.27, p.vi249-vi249

2016

Link zum Volltext

Verfügbarkeit prüfen

Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-Amino-4-oxo-4,6,7,8-tetrahydro-3 H-pyrimidino[5,4,6][1,4]thiazin-6-yl)-( S)-ethyl]-2,5-thienoylamino- l-glutamic acid (AG2034) : Comparison across sensitive and resistant human tumor cell lines

Biochemical pharmacology, 1999-03, Vol.57 (5), p.567-577

1999

Link zum Volltext

Verfügbarkeit prüfen

The effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers

International journal of antimicrobial agents, 2000-08, Vol.15 (4), p.283-289

2000

Link zum Volltext

Verfügbarkeit prüfen

Parabolic Growth Patterns in 96-Well Plate Cell Growth Experiments

In vitro cellular & developmental biology. Animal, 1999-05, Vol.35 (5), p.270-278

1999

Link zum Volltext

Verfügbarkeit prüfen

4-Methylpyrazole monitoring during haemodialysis of ethylene glycol intoxicated patients

European journal of clinical pharmacology, 1995, Vol.49 (3), p.211-213

1995

Link zum Volltext

Verfügbarkeit prüfen

Effect of Human Renal Cationic Transporter Inhibition on the Pharmacokinetics of Varenicline, a New Therapy for Smoking Cessation : An In Vitro-In Vivo Study: Addictions

Clinical pharmacology and therapeutics, 2008, Vol.83 (4), p.567-576

2008

Link zum Volltext

Verfügbarkeit prüfen

Plasma level-dependent effects of methylphenidate on task-related functional magnetic resonance imaging signal changes: Brain imaging

Psychopharmacologia, 2005, Vol.180 (4), p.624-633

2005

Link zum Volltext

Verfügbarkeit prüfen

Nonlinear Response Surface and Mixture Experiment Methodologies Applied to the Study of Synergism

Biometrical journal, 2004-02, Vol.46 (1), p.56-71

2004

Link zum Volltext

Verfügbarkeit prüfen

Thymidine and hypoxanthine protection patterns of the folic acid-enhanced synergies for combinations of trimetrexate plus a polyglutamylatable inhibitor of purine or thymidylate synthesis against human ileocecal HCT-8 cells

International journal of oncology, 2003-08, Vol.23 (2), p.401

2003

Link zum Volltext

Verfügbarkeit prüfen

Varenicline: new treatment with efficacy in smoking cessation

Drugs of today (Barcelona, Spain : 1998), 2007-02, Vol.43 (2), p.65

2007

Link zum Volltext

Verfügbarkeit prüfen

A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking Cessation

Clinical pharmacokinetics, 2010-12, Vol.49 (12), p.799-816

2010

Link zum Volltext

Verfügbarkeit prüfen

Implications for clinical pharmacodynamic studies of the statistical characterization of an in vitro antiproliferation assay

Journal of pharmacokinetics and biopharmaceutics, 1998-12, Vol.26 (6), p.717-733

1998

Link zum Volltext

Verfügbarkeit prüfen

Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients

Proceedings of the National Academy of Sciences - PNAS, 2022-08, Vol.119 (35), p.1-e2207531119

2022

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Effect of Human Renal Cationic Transporter Inhibition on the Pharmacokinetics of Varenicline, a New Therapy for Smoking Cessation: An In Vitro–In Vivo Study

2502 TAK-385, an oral GnRH antagonist: efficacy and safety results from a randomized phase 2 trial in prostate cancer patients (pts)

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes

Quantitative Assessment of Exposure-Response Relationships for the Efficacy and Tolerability of Varenicline for Smoking Cessation

Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers

The safety, tolerability, pharmacodynamics, and pharmacokinetics of oral TAK-994 in sleep deprived healthy male subjects

Plasma level-dependent effects of methylphenidate on task-related functional magnetic resonance imaging signal changes

Results of a phase 1, 4-period crossover, placebo-controlled, randomized, single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-925, a novel orexin 2 receptor agonist, in sleep-deprived healthy adults, utilizing modafinil as an active comparator

Ranitidine, 75 mg, over‐the‐counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro‐oesophageal reflux

The Search for Cytotoxic Synergy Between Anticancer Agents: a Case of Dorothy and the Ruby Slippers?

A Phase 1 single ascending dose study of a novel orexin 2 receptor agonist, TAK-925, in healthy volunteers (HV) and subjects with narcolepsy type 1 (NT1) to assess safety, tolerability, pharmacokinetics, and pharmacodynamic outcomes

Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: The critical role of polyglutamylation

Neo/adjuvant ADT to EBRT: Randomized phase 2 trial of the oral GnRH antagonist, TAK-385 (relugolix, RGX) and degarelix (DGX) in patients (pts) with prostate cancer (PC)

The effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers

Parabolic Growth Patterns in 96-Well Plate Cell Growth Experiments

4-Methylpyrazole monitoring during haemodialysis of ethylene glycol intoxicated patients

Effect of Human Renal Cationic Transporter Inhibition on the Pharmacokinetics of Varenicline, a New Therapy for Smoking Cessation : An In Vitro-In Vivo Study: Addictions

Plasma level-dependent effects of methylphenidate on task-related functional magnetic resonance imaging signal changes: Brain imaging

Nonlinear Response Surface and Mixture Experiment Methodologies Applied to the Study of Synergism

Thymidine and hypoxanthine protection patterns of the folic acid-enhanced synergies for combinations of trimetrexate plus a polyglutamylatable inhibitor of purine or thymidylate synthesis against human ileocecal HCT-8 cells

Varenicline: new treatment with efficacy in smoking cessation

A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking Cessation

Implications for clinical pharmacodynamic studies of the statistical characterization of an in vitro antiproliferation assay

Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients

Suchergebnisse filtern